Your session is about to expire
← Back to Search
Zanubrutinib + Pemetrexed for CNS Lymphoma
Study Summary
This trial evaluates a treatment for relapsed/refractory primary central nervous system lymphoma and isolated central nervous system relapse of B cell lymphoma. It assesses how well people respond, side effects, and safety.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a confirmed diagnosis of CNS lymphoma or secondary CNS involvement by diffuse large B cell lymphoma.I am mostly independent in my daily activities.I have B cell non-Hodgkin's lymphoma that can be measured.I do not have any serious illnesses that are not under control.I do not have any other active cancer except for allowed exceptions.I understand and can follow the study's requirements.I have not received any live vaccines recently.I have allergies or reactions to certain medications.I have been treated for lymphoma with specific medications.My cancer got worse during the first treatment or came back after it initially worked.My scans show no signs of lymphoma throughout my body.My blood tests show my organs and bone marrow are working well.I have eye lymphoma with a confirmed diagnosis and a measurable brain tumor.I have a bleeding disorder or had a recent clotting event.I am using effective birth control and will continue for 90 days after my last dose.I have an infectious disease that meets certain criteria.I am not on any immune or targeted therapy not listed in this study.I have a serious heart condition that is currently causing symptoms.
- Group 1: Induction Therapy + SOC Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any known risks associated with combining Induction Therapy and Standard of Care Treatment?
"There is some evidence of Induction Therapy + SOC Treatment's safety, so it earned a score of 2 on our team's scale. As this remains an exploratory Phase 2 trial, we are yet to find any data confirming its efficacy."
Is this research endeavor recruiting participants at the present time?
"Assessing clinicaltrials.gov, one can surmise that this medical trial is no longer enrolling patients. Initially posted on January 1st 2023, the study was revised for the last time December 23rd 2022. Unfortunately, however, there are 2299 other trials currently seeking participants at this moment in time."
Share this study with friends
Copy Link
Messenger